-+ 0.00%
-+ 0.00%
-+ 0.00%

PTC Therapeutics reports new Sephience PKU trial and real-world data showing sustained Phe control, diet liberalization

PUBT·08/24/2026 12:03:00
Listen to the news
PTC Therapeutics reports new Sephience PKU trial and real-world data showing sustained Phe control, diet liberalization
  • PTC Therapeutics outlined new Sephience (sepiapterin) trial and real-world analyses slated for presentation at the SSIEM meeting on Aug. 25-28.
  • Upcoming presentations point to sustained metabolic control in PKU, with many patients reaching normal-range blood phenylalanine quickly.
  • Data also suggest meaningful diet liberalization while maintaining recommended control, including in patients with more severe or historically less responsive disease.
  • Safety findings remained consistent with prior studies, supporting broader use across patient subgroups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608240800PR_NEWS_USPR_____NY31852) on August 24, 2026, and is solely responsible for the information contained therein.